Indeed, for prostate cancer, the risk estimate for elevated YKL-40 levels was below 1.0, indicating a reduced risk, following a similar effect pattern to that observed for type 2 diabetes [9]. The gene discussed is CHI3L1; the disease is prostate cancer.